Diarrhea

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day.

What is Diarrhea?

The term diarrhea (also spelled diarrhoea) refers to passage of loose, watery stools. The usual frequency of passing loose stools or watery stools in cases of diarrhea is at least three or more times a day.

Diarrhea Treatment

Diarrhea Symptoms

Diarrhea Causes

Diarrhea Prevention

Diarrhea Epidemiology

Diarrhea in Children

Acute Diarrhea

Chronic Diarrhea

Latest Diarrhea News and Research

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.

19 Apr 2021

Candidate coronavirus vaccines show promising results in early animal testing

A candidate vaccine that could provide protection against the COVID-19 virus and other coronaviruses has shown promising results in early animal testing.

17 Apr 2021

FDA approves immunotherapy for first-line treatment of advanced gastric cancer

Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.

16 Apr 2021

Researchers identify risk factors for SARS-CoV-2 reinfection

A team of scientists from the Capital Medical University and Peking University, China, has recently explored the factors responsible for the reactivation of SARS-CoV-2 infection among individuals who have recently recovered from COVID-19. The findings reveal that individuals with lower lymphocyte count or with two or fewer symptoms during the first COVID-19 episode are at higher risk of recurrent infection.

16 Apr 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Tapeworm infection drug blocks SARS-CoV-2 damage in the lungs

New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.

12 Apr 2021

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

The gut is a well-established route of infection and target for viral damage by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) symptoms.

8 Apr 2021

Unhealthy eating can have immediate effects on workplace performance

A recent study finds that unhealthy eating behaviors at night can make people less helpful and more withdrawn the next day at work.

7 Apr 2021

mRNA COVID-19 vaccines are highly effective among front liners, CDC study shows

The study, published in CDC's Morbidity and Mortality Weekly Report (MMWR), highlights the efficacy of mRNA vaccines in protecting against SARS-CoV-2 infection.

30 Mar 2021

Protein could be key to blocking the most common bacterial cause of food poisoning

Washington State University researchers have discovered a protein that could be key to blocking the most common bacterial cause of human food poisoning in the United States.

30 Mar 2021

Microbiota-derived molecules do not change the entry or replication of SARS-CoV-2 in intestinal cells

A study conducted at the University of Campinas in the state of São Paulo, Brazil, shows that compounds produced by gut microbiota (bacteria and other microorganisms) during fermentation of insoluble fiber from dietary plant matter do not affect the ability of the novel coronavirus SARS-CoV-2 to enter and replicate in cells lining the intestines.

30 Mar 2021

Repurposed heart and flu drugs that protect platelets improve survival of septic mice

Despite continued improvements in antibiotics and hospital intensive care, staph sepsis -; a bloodstream infection caused by Staphylococcus aureus bacteria -; still causes severe illness or death in 20 to 30 percent of patients who contract it.

24 Mar 2021

How could AI be used to predict infection outcomes?

Professor Frankel speaks to News-Medical about his latest research that investigated whether AI could be used to predict infection outcomes.

23 Mar 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021

Developing a COVID-19 vaccine using inactivated E. coli

A team of researchers inactivated whole-cell E.coli with a reduced genome and utilized this to express coronavirus-specific fusion peptides, demonstrating a potent anamnestic response.

19 Mar 2021

Could cinnamon modulate the immune response in severe COVID-19?

A new study describes the potential for two common plant products to make a difference in the management of severe COVID-19.

18 Mar 2021

Microbiota modulation and re-establishment of eubiosis could help curb COVID-19 complications

In the paper published in the journal Frontiers in Immunology, the researchers noted that since both the respiratory tract and the gastrointestinal mucosa are affected in COVID-19, it is possible that adjunctive therapies that modulate the gut-lung axis.

18 Mar 2021

COVID-19 is more difficult to diagnose in children and adolescents, finds study

The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 192 countries and territories, causing an enormous loss of lives and economic devastation.

17 Mar 2021